Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.08 USD
Change Today -0.07 / -3.26%
Volume 98.7K
OGXI On Other Exchanges
As of 8:10 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

oncogenex pharmaceutical inc (OGXI) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/2/14 - $11.84
52 Week Low
02/4/15 - $1.92
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

oncogenex pharmaceutical inc (OGXI) Related Businessweek News

No Related Businessweek News Found

oncogenex pharmaceutical inc (OGXI) Details

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. The company’s product candidates include Custirsen that is in Phase III clinical development for the treatment in men with metastatic castrate-resistant prostate cancer, as well as in patients with non-small cell lung cancer; and Apatorsen, which is in two Phase I and seven randomized Phase II trials for the treatment of bladder, lung, pancreatic, and prostate cancers. It also develops OGX-225 that is in pre-clinical development for the treatment of solid tumors. The company has a collaboration agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize Custirsen. OncoGenex Pharmaceuticals, Inc. is headquartered in Bothell, Washington.

35 Employees
Last Reported Date: 03/26/15

oncogenex pharmaceutical inc (OGXI) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $497.2K
Chief Financial Officer and Vice President
Total Annual Compensation: C$138.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: C$413.2K
Compensation as of Fiscal Year 2014.

oncogenex pharmaceutical inc (OGXI) Key Developments

OncoGenex Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

OncoGenex Pharmaceuticals, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss of $5.68 million, or $0.26 loss per share, compared to a net loss of $6.68 million, or $0.45 loss per share, for the same quarter ended December 31, 2013. Collaboration revenue was $5.65 million, compared to $8.6 million for the same quarter ended December 31, 2013. For the year, the company reported net loss of $26.24 million, or $1.45 loss per share, compared to a net loss of $31.85 million, or $2.17 loss per share, for the year ended December 31, 2013. Collaboration revenue was $27.12 million, compared to $29.88 million for the year ended December 31, 2013.

OncoGenex Pharmaceuticals, Inc. Proposes Amendment to Certificate of Incorporation

OncoGenex Pharmaceuticals, Inc. announced that at the AGM to be held on May 21, 2015, the shareholders will consider amendment to certificate of incorporation to increase authorized shares of common stock from 50,000,000 to 75,000,000.

OncoGenex Pharmaceuticals, Inc. to Report Q4, 2014 Results on Mar 26, 2015

OncoGenex Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Mar 26, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGXI:US $2.08 USD -0.07

OGXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OGXI.
View Industry Companies

Industry Analysis


Industry Average

Valuation OGXI Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOGENEX PHARMACEUTICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at